Citius Oncology Showcases Innovations at the 67th American Society of Hematology Annual Meeting

Citius Oncology at the 67th ASH Annual Meeting

Citius Oncology, Inc., a dedicated subsidiary of Citius Pharmaceuticals, Inc., is proud to announce its participation in the upcoming 67th American Society of Hematology (ASH) Annual Meeting, scheduled to occur from December 6 to 9, 2025, in Orlando, Florida. With a focus on advancing innovative cancer therapies, Citius will showcase its flagship product, LYMPHIR (denileukin diftitox-cxdl), at Booth #265 in the ASH Exhibit Hall.

About LYMPHIR

LYMPHIR is a novel immunotherapy recently approved by the U.S. Food and Drug Administration (FDA) aimed at treating adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL). This therapy has shown promising results for patients who have gone through at least one prior systemic treatment, representing a significant advancement in the therapeutic options available for this challenging disease.

The unique design of LYMPHIR features a recombinant fusion protein that strategically targets IL-2 receptors on malignant cells, delivering cytotoxic agents to eliminate cancerous tissues while sparing healthy ones. In clinical trials, LYMPHIR demonstrated a remarkable capacity to deplete regulatory T lymphocytes and activate immune responses against IL-2R-expressing tumors, marking it as a vital addition to oncology treatments.

Engaging with the Oncology Community

During the ASH Annual Meeting, Citius Oncology aims to foster discussions with healthcare professionals, researchers, and other stakeholders in the oncology field to explore the clinical benefits and possibilities presented by LYMPHIR. According to Leonard Mazur, Chairman and CEO of Citius Oncology, “This event provides a perfect platform to connect with key players in the CTCL community and discuss how LYMPHIR's innovative clinical profile can serve as an important treatment option for patients afflicted by cutaneous T-cell lymphoma.”

With over 25,000 attendees expected, including clinicians, scientists, and industry leaders, the ASH Annual Meeting stands as a premier event in hematology, showcasing state-of-the-art research and the latest advancements in hematologic innovation.

Understanding Cutaneous T-cell Lymphoma

Cutaneous T-cell lymphoma is recognized as the most prevalent form of cutaneous non-Hodgkin lymphoma (NHL). This condition arises when T-cells, crucial for immune response, undergo malignant transformation, leading to severe complications and manifestations including debilitating skin lesions. Mycosis fungoides (MF) and Sézary syndrome (SS) are its most common forms, and progression can be slow, but untreated cases can evolve into highly malignant stages with poor prognoses.

Patients typically experience cycles of treatment as the disease can often resist various therapies, underscoring the necessity for novel solutions like LYMPHIR that have the potential to enhance patient outcomes dramatically.

Citius Oncology's Future

Citius Oncology is strategically positioned within the biotech industry for growth, backed by a robust intellectual property framework and an expanding pipeline. The FDA's recent approval of LYMPHIR marked a significant milestone, and the company estimates that the initial market for this therapy exceeds $400 million, a figure that is expected to grow as healthcare professionals recognize the value of this innovative treatment.

As the company continues to develop and commercialize targeted oncology therapies, it remains committed to advancing patient care and outcomes through groundbreaking pharmaceutical solutions. For more information about Citius Oncology and LYMPHIR, visit Citius Oncology.